Bratton Capital Management, L.P. Aquestive Therapeutics, Inc. Transaction History
Bratton Capital Management, L.P.
- $32.5 Billion
- Q2 2025
A detailed history of Bratton Capital Management, L.P. transactions in Aquestive Therapeutics, Inc. stock. As of the latest transaction made, Bratton Capital Management, L.P. holds 9,810,958 shares of AQST stock, worth $48.7 Million. This represents 100.0% of its overall portfolio holdings.
Number of Shares
9,810,958
Previous 9,810,958
-0.0%
Holding current value
$48.7 Million
Previous $28.5 Billion
14.14%
% of portfolio
100.0%
Previous 100.0%
Shares
2 transactions
Others Institutions Holding AQST
# of Institutions
125Shares Held
47.4MCall Options Held
64.2KPut Options Held
204K-
Black Rock Inc. New York, NY5.45MShares$27.1 Million0.0% of portfolio
-
Vanguard Group Inc Valley Forge, PA4.33MShares$21.5 Million0.0% of portfolio
-
Israel Englander Millennium Management LLC | New York, Ny2.98MShares$14.8 Million0.01% of portfolio
-
Perceptive Advisors LLC New York, NY2.19MShares$10.9 Million0.32% of portfolio
-
Geode Capital Management, LLC Boston, MA1.98MShares$9.81 Million0.0% of portfolio
About Aquestive Therapeutics, Inc.
- Ticker AQST
- Exchange NASDAQ
- Sector Healthcare
- Industry Drug Manufacturers—Specialty & Generic
- Shares Outstandng 53,350,700
- Market Cap $265M
- Description
- Aquestive Therapeutics, Inc., a pharmaceutical company, focuses on identifying, developing, and commercializing various products to address unmet medical needs in the United States and internationally. The company markets Sympazan, an oral soluble film formulation of clobazam for the treatment of lennox-gastaut syndrome; Suboxone, a sublingual f...